Ulipristal Acetate is Used for emergency contraception within 120 hours after unprotected intercourse, particularly effective in overweight women. It was first introduced by Laboratoire Hra Pharma in its drug Ella on Aug 13, 2010. 2 different companies have introduced drugs containing Ulipristal Acetate.

Ulipristal Acetate Patents

Given below is the list of patents protecting Ulipristal Acetate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Ella	US8426392	Method for providing emergency contraception	Jun 12, 2030	Lab Hra Pharma
Ella	US8962603	Method for post coital contraception in overweight or obese female subjects using ulipristal acetate	Jun 12, 2030	Lab Hra Pharma
Ella	US8512745	Ulipristal acetate tablets	Jun 02, 2030	Lab Hra Pharma
Ella	US10159681	Method for on-demand contraception	Apr 13, 2030	Lab Hra Pharma
Ella	US10772897	Method for on-demand contraception	Apr 13, 2030	Lab Hra Pharma
Ella	US9283233	Method for on-demand contraception	Apr 13, 2030	Lab Hra Pharma
Ella	US8735380	Ulipristal acetate tablets	Feb 20, 2029	Lab Hra Pharma
Ella	US9844510	Ulipristal acetate tablets	Dec 08, 2028	Lab Hra Pharma

Add above patents to watchlist

Ulipristal Acetate's Family Patents

Full family tree

Ulipristal Acetate Generic API Manufacturers

Only one generic application has been filed for Ulipristal Acetate.

Given below is the list of companies who have filed for Ulipristal Acetate generic, along with the locations of their manufacturing plants worldwide.